8-K: Fortress Biotech Reports Q1 2024 Financial Results and Pipeline Progress

Fortress Biotech announced a 7% year-over-year increase in product revenue for Q1 2024, driven by strong growth in flagship products and advancements in its clinical pipeline.

Summary

• Fortress Biotech reported a 7% increase in product revenue year-over-year for the first quarter of 2024, reaching $13.0 million, primarily driven by Qbrexza and Accutane.
• The company's flagship products, Qbrexza and Accutane, experienced over 20% year-over-year growth.
• The FDA accepted the New Drug Application (NDA) for DFD-29, with a PDUFA goal date of November 4, 2024.
• Fortress anticipates up to three regulatory approvals for NDAs and BLAs in the next 12 months and potentially a fourth BLA filing as early as 2025.
• The company dosed the first patient in a Phase 2 study for Triplex for CMV control in liver transplant patients and received NIH grant funding for cell and gene therapy candidates.
• Fortress's consolidated cash, cash equivalents, and restricted cash totaled $85.8 million as of March 31, 2024, an increase of $2.5 million from the end of 2023.
• Consolidated net loss attributable to common stockholders was $(17.7) million, or $(1.03) per share, for the first quarter ended March 31, 2024, compared to a net loss of $(23.5) million, or $(3.47) per share for the same period in 2023.
• Research and development expenses decreased to $24.8 million in Q1 2024 from $39.5 million in Q1 2023.
• Selling, general, and administrative costs also decreased to $17.9 million in Q1 2024 from $25.3 million in Q1 2023.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong revenue growth and pipeline advancements, but the net loss and the CRL for cosibelimab temper the overall sentiment. The company is making progress but still faces challenges.

Positives

• Product revenue increased by 7% year-over-year, reaching $13.0 million in Q1 2024.
• Flagship products Qbrexza and Accutane experienced over 20% year-over-year growth.
• The FDA accepted the NDA for DFD-29, with a PDUFA goal date set for November 4, 2024.
• The company anticipates multiple regulatory approvals in the near term, including up to three NDA and BLA approvals in the next 12 months.
• Fortress secured NIH grant funding for cell and gene therapy development.
• The company's cash position increased by $2.5 million during the quarter.
• Net loss per share improved from $(3.47) to $(1.03) year-over-year.
• Research and development expenses decreased significantly year-over-year.
• Selling, general, and administrative costs decreased significantly year-over-year.

Negatives

• The company reported a net loss attributable to common stockholders of $(17.7) million for Q1 2024.
• The company received a complete response letter (CRL) from the FDA for the cosibelimab BLA, citing issues at a third-party contract manufacturing organization.
• The company is still reliant on external funding to support its operations and pipeline development.

Risks

• The company's growth strategy relies on successful product development, regulatory approvals, and commercialization.
• Fortress needs substantial additional funds and faces uncertainties relating to financings.
• There are risks associated with identifying, acquiring, closing, and integrating product candidates.
• The company faces challenges in attracting, integrating, and retaining key personnel.
• The products under development are in early stages and subject to uncertainties relating to preclinical and clinical testing.
• There are risks associated with obtaining regulatory approval for products under development.
• The company faces risks in successfully commercializing products for which they receive regulatory approval.
• Fortress relies on third-party manufacturing, marketing, and distribution of its and its partner companies' products and product candidates.
• The company is subject to government regulation, patent and intellectual property matters, and competition.

Future Outlook

Fortress anticipates up to three NDA and BLA regulatory approvals within the next 12 months and potentially a fourth BLA filing as early as 2025. The company also expects multiple data readouts this year, including topline data from the Phase 1b/2a clinical trial of AJ201, data from the Phase 1b clinical trial of dotinurad, and topline Phase 2 clinical data of Triplex.

Management Comments

• Lindsay A. Rosenwald, M.D., Fortress Chairman, President and Chief Executive Officer, said, 'We achieved first quarter year-over-year product revenue growth of 7%, which was driven by greater than 20% year-over-year growth in our flagship products, Qbrexza and Accutane.'
• Lindsay A. Rosenwald, M.D., stated that DFD-29 has the potential to be the only oral, systemic therapy to address inflammatory lesions and erythema from rosacea.

Industry Context

The announcement reflects the ongoing trend in the biopharmaceutical industry of focusing on late-stage pipeline development and regulatory approvals. The company's focus on dermatology, oncology, and rare diseases aligns with areas of significant unmet medical need and market opportunity. The partnerships with leading academic institutions and biopharmaceutical companies are also a common strategy in the industry to leverage expertise and resources.

Comparison to Industry Standards

• The 7% year-over-year revenue growth is a positive sign, but it is important to compare this to the growth rates of similar biopharmaceutical companies with marketed products. For example, companies like Dermavant Sciences (DRMT) or Arcutis Biotherapeutics (ARQT) in the dermatology space would be relevant comparators.
• The decrease in R&D expenses could be a positive sign of efficiency, but it needs to be assessed in the context of the company's pipeline progress and compared to industry averages. Companies like Biohaven (BHVN) or Neurocrine Biosciences (NBIX) could be used as benchmarks for R&D spending.
• The company's cash position of $85.8 million is a key metric, and it should be compared to the cash burn rates of similar companies to assess its runway. Companies like Madrigal Pharmaceuticals (MDGL) or Viking Therapeutics (VKTX) could be used as benchmarks for cash burn.
• The regulatory milestones, such as the FDA acceptance of the DFD-29 NDA and the anticipated BLA resubmission for cosibelimab, are critical for the company's future growth and should be compared to the timelines and success rates of similar programs in the industry.

Stakeholder Impact

• Shareholders may be positively impacted by the revenue growth and pipeline advancements, but the net loss and the CRL for cosibelimab may cause concern.
• Employees may be impacted by the company's growth and development activities.
• Patients may benefit from the potential approval of new therapies, such as DFD-29 and cosibelimab.
• Suppliers and creditors may be impacted by the company's financial performance and cash position.

Next Steps

• The company will focus on the PDUFA goal date for DFD-29 on November 4, 2024.
• Fortress intends to resubmit the BLA for cosibelimab in mid-2024.
• The company will continue to advance its clinical trials, including the Phase 2 study for Triplex and the Phase 1b trial for dotinurad.
• Fortress will announce data from the Phase 1b clinical trial of dotinurad in mid-2024.
• The company will announce topline data from the Phase 2 clinical trial of Triplex in the fourth quarter of 2024.

Key Dates

Keywords

biopharmaceutical, clinical trials, regulatory approvals, product revenue, dermatology, oncology, rare diseases, NDA, BLA, DFD-29, Triplex, cosibelimab, Qbrexza, Accutane, financial results